These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 33032013)
21. A retrospective evaluation of COVID-19 patients treated with Tocilizumab: who should be treated? Çelik Ekinci S; Akkaya Işık S J Infect Dev Ctries; 2021 Dec; 15(12):1825-1832. PubMed ID: 35044939 [TBL] [Abstract][Full Text] [Related]
22. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of Tocilizumab in COVID-19: Single-Center Experience. Kaya S; Kavak S Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235 [TBL] [Abstract][Full Text] [Related]
24. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials. Baker EH; Patel K; Ball J; Edwards S; Harrison TS; Kaul A; Koh M; Krishna S; Leaver S; Kumar V; Forton DM Br J Clin Pharmacol; 2021 Mar; 87(3):1584-1586. PubMed ID: 32656822 [No Abstract] [Full Text] [Related]
25. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors. Cure E; Kucuk A; Cure MC Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908 [TBL] [Abstract][Full Text] [Related]
26. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2. Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome. Oliynyk O; Barg W; Slifirczyk A; Oliynyk Y; Gurianov V; Rorat M Viruses; 2021 Jun; 13(6):. PubMed ID: 34205217 [TBL] [Abstract][Full Text] [Related]
28. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Frigault MJ; Nikiforow S; Mansour MK; Hu ZH; Horowitz MM; Riches ML; Hematti P; Turtle CJ; Zhang MJ; Perales MA; Pasquini MC Blood; 2020 Jul; 136(1):137-139. PubMed ID: 32457999 [No Abstract] [Full Text] [Related]
29. Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes. Valencia Sanchez C; Theel E; Binnicker M; Toledano M; McKeon A Neurology; 2021 Dec; 97(23):e2262-e2268. PubMed ID: 34635560 [TBL] [Abstract][Full Text] [Related]
30. Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series. Beltrão BA; Teixeira RC; Porto DB J Investig Med High Impact Case Rep; 2021; 9():23247096211037442. PubMed ID: 34334015 [TBL] [Abstract][Full Text] [Related]
31. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience. Jiménez-Brítez G; Ruiz P; Soler X Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713 [No Abstract] [Full Text] [Related]
32. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770 [TBL] [Abstract][Full Text] [Related]
33. Encephalopathy and COVID-19: a case report. Lazraq M; Benhamza S; Saadaoui S; Hayar S; Louardi M; Moujahid H; Bensaid A; Miloudi Y; Harrar NE Pan Afr Med J; 2021; 38():139. PubMed ID: 33912309 [TBL] [Abstract][Full Text] [Related]
34. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. Du P; Geng J; Wang F; Chen X; Huang Z; Wang Y Int J Med Sci; 2021; 18(6):1356-1362. PubMed ID: 33628091 [TBL] [Abstract][Full Text] [Related]
35. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19. Ali A; Kamjani MH; Kesselman MM Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623 [TBL] [Abstract][Full Text] [Related]